With a portfolio spanning hematology and solid tumors, the company is engaged in development of a diverse pipeline of novel therapeutics. Key products include Brukinsa, an orally available BTK inhibitor, along with Tevimbra and Pamiparib. Analysts rate the stock "Strong Buy" with a 12-month price target of $370.25.
Cyborg Score Rationale
The company demonstrated exceptional revenue growth of 55% year-over-year to $3.81 billion in 2024. Operating losses improved significantly, declining 27% to $644.79 million. Strong analyst support and expanding global commercialization underpin confidence.
Top Insights
Revenue grew 55% in 2024 to $3.81 billion, demonstrating accelerating commercial traction
Rapid commercial expansion and operational efficiencies position the company for enhanced profitability and margin improvement
Extensive pipeline includes 25+ clinical and preclinical programs spanning multiple cancer indications and mechanisms
Market capitalization exceeds $200 billion, placing BeOne in the mega-capitalization category
Named Competitors
Revlimid/Imbruvica — Established hematologic cancer therapies
Opdivo/Yervoy — Immuno-oncology franchise
Keytruda — Leading checkpoint inhibitor
Recent Developments
(February 2026) Barclays raised price target to $394 from $385
(February 2026) Bernstein reiterated Buy rating with $414 price target
(January 2026) Announced new Phase 3 head-to-head trial targeting CLL market leaders
Open the full interactive BeOne Medicines AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.